Intra-Cellular Therapies Shares Outstanding 2013-2022 | ITCI

Intra-Cellular Therapies shares outstanding history from 2013 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Intra-Cellular Therapies shares outstanding for the quarter ending March 31, 2022 were 0.093B, a 14.4% increase year-over-year.
  • Intra-Cellular Therapies 2021 shares outstanding were 0.081B, a 15.47% increase from 2020.
  • Intra-Cellular Therapies 2020 shares outstanding were 0.07B, a 27.51% increase from 2019.
  • Intra-Cellular Therapies 2019 shares outstanding were 0.055B, a 0.87% increase from 2018.
Intra-Cellular Therapies Annual Shares Outstanding
(Millions of Shares)
2021 81
2020 70
2019 55
2018 55
2017 46
2016 43
2015 36
2014 29
2013 17
2012 6
Intra-Cellular Therapies Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 93
2021-12-31 81
2021-09-30 81
2021-06-30 81
2021-03-31 81
2020-12-31 70
2020-09-30 70
2020-06-30 66
2020-03-31 65
2019-12-31 55
2019-09-30 55
2019-06-30 55
2019-03-31 55
2018-12-31 55
2018-09-30 55
2018-06-30 55
2018-03-31 55
2017-12-31 46
2017-09-30 43
2017-06-30 43
2017-03-31 43
2016-12-31 43
2016-09-30 43
2016-06-30 43
2016-03-31 43
2015-12-31 36
2015-09-30 35
2015-06-30 35
2015-03-31 31
2014-12-31 29
2014-09-30 29
2014-06-30 29
2014-03-31 26
2013-12-31 17
2013-09-30 18
2013-06-30 15
2013-03-31 15
2012-12-31
2012-09-30 6
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.373B $0.084B
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $164.215B 9.99
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.343B 16.33
Biohaven Pharmaceutical Holding (BHVN) United States $10.057B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.540B 0.00
Emergent Biosolutions (EBS) United States $1.675B 7.17
Arcus Biosciences (RCUS) United States $1.287B 32.64
Myovant Sciences (MYOV) United Kingdom $0.927B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.347B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.113B 23.10
SQZ Biotechnologies (SQZ) United States $0.094B 0.00